Low-renin hypertension: a distinct phenotype enabling mechanism-based treatment
Clicks: 8
ID: 322695
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
8 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #22 of 359 articles by views in the journal of clinical endocrinology & metabolism
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 359 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Low-renin hypertension is increasingly recognized as a common and clinically important form of hypertension. Expanded screening for primary aldosteronism has revealed many individuals with suppressed renin who do not meet the diagnostic criteria for aldosterone excess, yet exhibit features consistent with sodium retention or increased mineralocorticoid activity. This review synthesizes evidence from targeted literature searches on the epidemiology, mechanisms, diagnostic challenges, and treatment of low-renin hypertension. Early studies proposed renin, in the presence of hypertension, as a marker of excess sodium retention and volume expansion, suggesting that renin could guide individualized therapy. Adoption of a renin-guided treatment approach was historically limited by assay variability and concerns regarding adverse effects from high-dose mineralocorticoid receptor antagonists. However, improvements in renin assay performance, increased accessibility and use of renin testing, and the availability of lower-dose and better-tolerated mineralocorticoid receptor antagonists have renewed interest in this strategy. Low-renin hypertension encompasses primary aldosteronism, conditions that mimic mineralocorticoid excess, and disorders of renal tubular sodium transport. Across this spectrum, patients respond more favorably to therapies targeting sodium retention: mineralocorticoid receptor antagonists, epithelial sodium channel inhibitors, or thiazide diuretics, than to agents directed primarily at vasoconstriction. Recognition of low-renin hypertension as a distinct phenotype enables mechanism-based therapy and may improve blood pressure control, reduce medication burden, and mitigate long-term cardiovascular risk.
| Reference Key |
openalex_W7171350489
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Sonali Shah, Peter J. Fuller, Morag J. Young, Jun Yang |
| Journal | the journal of clinical endocrinology & metabolism |
| Year | 2026 |
| DOI |
10.1210/clinem/dgag292
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.